#36: A Novel Interactive Safety Graphic to Evaluate Potential Drug-Induced Hepatotoxicity
James Buchanan, PharmD
- Drug Safety Consultant
- Covilance LLC, United States
Dr. James Buchanan is presently an independent drug safety consultant. After leaving Gilead Sciences, Dr. Buchanan started the drug safety department at Tularik Inc where he acted as Chief Safety Officer until the company was acquired 5 years later by Amgen. Following the merger with Amgen, he moved to Nuvelo to establish a drug safety department and act as Chief Safety Officer where he also had responsibility for clinical operations, biostatistics and data management. Dr. Buchanan next served with BioSoteria for 5 years as the head of the medical and safety consulting group, which was subsequently acquired by Dohmen Life Science Services. Dr. Buchanan is currently president of Covilance, LLC, a drug safety consulting service.
Jeremy Wildfire, MSc
- Senior Data Scientist
- Rho, Inc. , United States
I have worked as a biostatistician for the NIAID funded Inner City Asthma Consortium (ICAC) for nearly 10 years. My work with ICAC has included the development of the Composite Asthma Severity Index, the first quantitative measure of asthma severity, and the analysis of multiple late-stage clinical trials for novel asthma treatments. I've paid special attention to statistical graphics and have worked created many interactive web-based tools for analyzing health-related data.